NEW HOPE FOR SERIOUS INFECTIONS

Cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives. Our drug candidates include CD101 IV, a long-acting echinocandin antifungal, CD101 topical, and C001, developed using our Cloudbreak™ immunotherapy platform.

Cidara seeks to improve patients’ lives through the discovery, development and commercialization of novel, best-in-class, anti-infectives. Our initial portfolio is comprised of proprietary product candidates for the treatment of serious fungal infections.

CD101 IV

Our lead product candidate, CD101 IV, is a novel molecule in the echinocandin class of antifungals. We are initially developing CD101 IV for the treatment of systemic Candida infections. We intend to complete IND-enabling studies and start a Phase I clinical trial in 2015.

CD101 Topical

We are developing CD101 topical for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC). CD101 has demonstrated potent fungicidal activity against Candida species in vitro and has unique physical properties allowing its formulation as a topical agent.

Cloudbreak™

Cloudbreak is a proprietary immunotherapy platform being used to create compounds that direct a patient’s immune cells to attack pathogens that cause infectious disease. Our first candidate, C001, is being developed for the treatment of invasive aspergillosis.

Opportunity

Fungal infections pose significant medical challenges in both the hospital and outpatient settings. These infections typically afflict immunocompromised persons including patients undergoing organ or bone marrow transplantation, chemotherapy, or patients with AIDS.

GET IMPORTANT NEWS AND UPDATES BY EMAIL